Literature DB >> 29843148

Target Door-to-Needle Time for Tissue Plasminogen Activator Treatment with Magnetic Resonance Imaging Screening Can Be Reduced to 45 min.

Denis Sablot1,2, Ioana Ion1, Khaled Khlifa3, Geoffroy Farouil4, Franck Leibinger5, Nicolas Gaillard1,6, Alexandre Laverdure3, Zoubir Mourad Bensalah4, Julie Mas1, Bénédicte Fadat1, Philippe Smadja4, Adélaïde Ferraro-Allou1, Jean-Marie Bonnec3, Nadège Olivier1, Anaïs Dutray1, Maxime Tardieu4, Adrian Dumitrana1, Aymeric Guibal4, Snejana Jurici1, Jean-Louis Bertrand4, Thibaut Allou1, Caroline Arquizan6, Alain Bonafe4,7.   

Abstract

OBJECTIVE: The purpose of this study was to demonstrate that the median door-to-needle (DTN) time for intravenous tissue plasminogen activator (tPA) treatment can be reduced to 45 min in a primary stroke centre with MRI-based screening for acute ischaemic stroke (AIS).
METHODS: From February 2015 to February 2017, the stroke unit of Perpignan general hospital, France, implemented a quality-improvement (QI) process. During this period, patients who received tPA within 4.5 h after AIS onset were included in the QI cohort. Their clinical characteristics and timing metrics were compared each semester and also with those of 135 consecutive patients with AIS treated by tPA during the 1-year pre-QI period (pre-QI cohort).
RESULTS: In the QI cohort, 274 patients (92.5%) underwent MRI screening. While the demographic and baseline characteristics were not significantly different between cohorts, the median DTN time was significantly lower in the QI than in the pre-QI cohort (52 vs. 84 min; p < 0.00001). Within the QI cohort, the median DTN time for each semester decreased from 65 to 44 min (p < 0.00001) and the proportion of treated patients with a DTN time ≤45 min increased from 25 to 58.9% (p < 0.0001). Overall, DTN time improvement was associated with a better outcome at 3 months (patients with a modified Rankin Scale score between 0 and 2: 61.8% in the QI vs. 39.3% in the pre-QI cohort; p < 0.0001).
CONCLUSIONS: A QI process can reduce the DTN within 45 min with MRI as a screening tool.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Stroke unit; Thrombolysis

Mesh:

Substances:

Year:  2018        PMID: 29843148     DOI: 10.1159/000489568

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  3 in total

1.  MRI-based thrombolytic therapy in patients with acute ischemic stroke presenting with a low NIHSS.

Authors:  Shahram Majidi; Marie Luby; John K Lynch; Amie W Hsia; Richard T Benson; Chandni P Kalaria; Zurab Nadareishvili; Lawrence L Latour; Richard Leigh
Journal:  Neurology       Date:  2019-09-13       Impact factor: 9.910

2.  Routine use of FLAIR-negative MRI in the treatment of unknown onset stroke.

Authors:  Malik M Adil; Marie Luby; John K Lynch; Amie W Hsia; Chandni P Kalaria; Zurab Nadareishvili; Lawrence L Latour; Richard Leigh
Journal:  J Stroke Cerebrovasc Dis       Date:  2020-07-04       Impact factor: 2.677

3.  Shortening time to reperfusion after transfer from a primary to a comprehensive stroke center.

Authors:  Denis Sablot; Geoffroy Farouil; Alexandre Laverdure; Caroline Arquizan; Alain Bonafe
Journal:  Neurol Clin Pract       Date:  2019-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.